RxDoctor Payments Data

Julie Adams, NP

Nurse Practitioner · Tyler, TXNPI 1023164456

Payments from drug & device makers

$1,563in general payments, 2019–2025

Across 80 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$486
  • Eisai Inc.$210
  • Lilly USA, LLC$176
  • UCB, Inc.$132
  • Biohaven Pharmaceutical Holding Company Ltd.$127
  • Amgen$123
  • plus $309 from 12 others

What the payments were for

  • Food & beverage$1,563100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,563 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$49,047
Medicare patients
327
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate39$66,618
QuliptaAtogepant22$23,247
UbrelvyUbrogepant19$20,208
Emgality PenGalcanezumab-Gnlm13$12,372
Aimovig AutoinjectorErenumab-Aooe16$11,389
Memantine Hcl337$8,358
GemtesaVibegron12$5,309
Rivastigmine11$2,766
Gabapentin160$2,153
Donepezil Hcl233$1,936
Primidone77$1,555
Rasagiline Mesylate14$1,524
Pregabalin66$1,446
Levetiracetam104$1,391
Duloxetine Hcl63$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$51$66,61839 claims
AbbVieQulipta, Ubrelvy$486$43,45541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →